淋巴系恶性肿瘤患者mRNA新冠疫苗接种后T细胞应答常可检出而未必血清阳转
该前瞻性研究评估263例淋巴系恶性肿瘤患者和167名年龄性别匹配健康对照完成mRNA新冠疫苗全程接种后的血清学与T细胞应答。
要点
- 99例受检患者中86%有T细胞应答,74%血清阴性者仍有T细胞应答。
核心结论
- 淋巴系恶性肿瘤患者接种mRNA新冠疫苗后血清学应答率偏低,尤其在抗CD20治疗者中。
研究设计与样本
- 前瞻性研究纳入263例慢性淋巴细胞白血病、B细胞和T细胞淋巴瘤及多发性骨髓瘤患者。
- 对照为167名年龄和性别匹配的健康受试者,评估完成mRNA疫苗全程接种后的血清学和T细胞应答。
主要发现
- 99例患者中86例(86%)检出T细胞应答,74%血清阴性者仍有T细胞应答。
临床怎么用
- 淋巴系恶性肿瘤患者接种mRNA疫苗后应严格维持所有防护措施。
- 尤其接受抗CD20抗体治疗者,疫苗接种获得的保护可能有限。
局限性
- T细胞应答仅在99例患者中评估。
- 研究未报告T细胞应答与临床保护力之间的直接关联数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients affected by lymphoid malignancies (LM) are frequently immune-compromised, suffering increased mortality from COVID-19. This prospective study evaluated serological and T-cell responses after complete mRNA vaccination in 263 patients affected by chronic lymphocytic leukaemia, B- and T-cell lymphomas and multiple myeloma. Results were compared with those of 167 healthy subjects matched for age and sex. Overall, patient seroconversion rate was 64·6%: serological response was lower in those receiving anti-cancer treatments in the 12 months before vaccination: 55% vs 81·9% (P < 0·001). Anti-CD20 antibody plus chemotherapy treatment was associated with the lowest seroconversion rate: 17·6% vs. 71·2% (P < 0·001). In the multivariate analysis conducted in the subgroup of patients on active treatment, independent predictors for seroconversion were: anti-CD20 treatment (P < 0·001), aggressive B-cell lymphoma diagnosis (P = 0·002), and immunoglobulin M levels <40 mg/dl (P = 0·030). The T-cell response was evaluated in 99 patients and detected in 85 of them (86%). Of note, 74% of seronegative patients had a T-cell response, but both cellular and humoral responses were absent in 13·1% of cases. Our findings raise some concerns about the protection that patients with LM, particularly those receiving anti-CD20 antibodies, may gain from vaccination. These patients should strictly maintain all the protective measures.
引用
- Marasco V, Carniti C, Guidetti A, et al. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. Br J Haematol. 2021. PMID: 34649298. doi:10.1111/bjh.17877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。